PERTH, Australia – Sydney-based Immutep Ltd. unveiled new data for its phase I immunotherapy study that showed a long-lasting and durable response and an overall response rate of 61 percent in a melanoma study combining its lead immunotherapy with Merck's anti-PD-1 therapy Keytruda (pembrolizumab).